family with sequence similarity 50 member BGenealiases: D6S2654E · X5L
Q-omics provides the consensus-scored FAM50B profile across patient tissues and cancer cell-line models. FAM50B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM50B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM50B RNA expression shows 15,609 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, THCA, and PCPG as cancer lineages where FAM50B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM50B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM50B survival associations across molecular data types. FAM50B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM50B RNA expression–survival associations across cancer types. High FAM50B expression shows unfavorable associations in LGG and STAD, but favorable associations in KIRC, MESO, UVM and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM50B RNA expression.
This table summarizes FAM50B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM50B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM50B shows lower tumor expression in THCA, BLCA, KICH, UCEC, BRCA and COAD. The THCA box plot shows higher FAM50B RNA expression in normal versus tumor tissue (log2 FC = −0.844, t-test p < 0.001).
This table shows molecular features associated with FAM50B in patient tissues and cancer cell lines. In patient samples, FAM50B shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM50B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
